期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

PCSK9抑制剂Evolocumab和Alirocumab降低血脂和减少心血管事件的有效性和安全性评价 被引量：2

Efficacy and Safety of Evolocumab and Alirocumab in Reducing Lipids and Cardiovascular Events
下载PDF
导出
摘要 1文献来源研究一：Sabatine MS,Giugliano RP,Wiviott SD,et al.Efficacy and safety of Evolocumab inreducing lipids and cardiovascular events[J].N EnglJ Med,2015,372（16）：1500-1509.研究二：Robinson JG,Farnier M,Krempf M,
作者 刘金来 李苏华
机构地区 中山大学附属第三医院心血管内科
出处 《循证医学》 CSCD 2015年第6期334-338,共5页 The Journal of Evidence-Based Medicine
关键词 前蛋白转化酶枯草溶菌素9(PCSK9) Evolocumab Alirocumab 低密度脂蛋白胆固醇 心血管事件 proprotein convertase subtilisin- kexin type 9 Evolocumab Alirocumab low - density lipoprotein cholesterol cardiovascular event
分类号 R54 [医药卫生—心血管疾病]
  • 相关文献

参考文献12

  • 1Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/ AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association task force on practice guidelines [J]. J Am Coll Cardiol, 2014, 63 (25 Pt B) :2889-2934.
  • 2Jukema JW, Cannon CP, de Craen AJ, et al. The controversies of statin therapy: Weighing the evidence [ J ]. J Am Coil Cardiol, 2012,60(10) :875-881.
  • 3Giugliano RP, Sabatine MS. Are PCSK9 inhibitors the next breakthrough in the cardiovascular field? [J]. J Am Coil Cardiol, 2015,65(24) :2638-2651.
  • 4Sahebkar A, Simental- Mendia LE, Guerrero- Romero F, et al. Effect of statin therapy on plasma PCSK9 concentrations: A systematic review and meta- analysis of clinical trials [J]. Diabetes Obes Metab, 2015,17( 11 ) : 1042-1055.
  • 5Koren M J, Scott R, Kim JB, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL) : A randomised, double- blind, placebo-controlled, phase 2 study [J]. Lancet, 2012,380 (9858) : 1995-2006.
  • 6Stein EA, Mellis S, Yancopoulos GD, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol [J]. N Engl J Med, 2012,366(12) : 1108-1118.
  • 7Giugliano RP, Desai NR, Kohli P, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57 ) : A ran- domised, placebo-controlled, dose-ranging, phase 2 study [J]. Lancet, 2012,380(9858) :2007-2017.
  • 8Raal F, Scott R, Somaratne R, et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: The reduction of LDL-C with PCSK9 inhibition in heterozygous familial hypercholesterolemia disorder (RUTHERFORD) randomized trial [J]. Circulation, 2012,126(20) :2408-2417.
  • 9Roth EM, McKenney JM, Hanotin C, et al. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia [J]. N Engl J Med, 2012,367(20) : 1891-1900.
  • 10McKenney JM, Koren M J, Kereiakes DJ, et al. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy [ J]. J Am Coil Cardiol, 2012,59 (25) : 2344-2353.

同被引文献41

引证文献2

二级引证文献9

循证医学
2015年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部